Figure 3 | Scientific Reports

Figure 3

From: Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients’ sera

Figure 3

Levels of anti-IFX antibodies (ADA) and IFX, measured by: (A) ELISA in the plasma of 36 patients (i.e. those with IFX < 3 μg mL−1) and (B) SPR (76 patients). Red dots highlight the patients in which ADA were detectable despite measurable IFX levels. ADA are expressed as μg Equivalents mL−1, to indicate that the ADA used for the calibration curves are different from those produced by the patients.

Back to article page